Financials
Financial year 2025
Rayos Medicinal from Knokke-Heist, company number BE0792959360, closed financial year 2025 with a result of € 301,561 after tax. For that financial year Rayos Medicinal recorded a gross margin of € 399,185 and equity of € 591,129. Compared with financial year 2024, the result moved from € 180,721 to € 301,561. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 30, 2026.
€ 591,129
▲ 104% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 301,561
▲ 67% vs 2024
Profit after tax over the fiscal year.
€ 551,217
▲ 121% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 590,129.
People and assets in 2025
€ 2,316
▼ 38% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4,477
▲ € 3,674 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 150,340
▲ 74% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 140,952 | € 237,699 | € 399,185 | ▲ 68% |
| Profit after taxes | € 107,847 | € 180,721 | € 301,561 | ▲ 67% |
| Equity | € 108,847 | € 289,568 | € 591,129 | ▲ 104% |
| Total debts | € 46,655 | € 88,047 | € 154,816 | ▲ 76% |
| Cash | € 18,192 | € 249,293 | € 551,217 | ▲ 121% |
| Retained profit | € 107,847 | € 288,568 | € 590,129 | ▲ 105% |
| Bank debt | € 0 | € 738 | € 0 | ▼ 100% |
| Balance sheet total | € 155,502 | € 377,615 | € 745,945 | ▲ 98% |
Key figures of Rayos Medicinal, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Rayos Medicinal?
What happened at Rayos Medicinal in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 301,561 (▲ 67% vs 2024). Source: NBB ↗
- New establishment in Knokke-Heist. KBO
- Start of the company according to the CBE. KBO
- Jan Van der Heyden became a director. NBB
- Vanessa Schelfhout became a director. NBB
In short
From € 107,847 profit in 2023 to € 301,561 profit in 2025.
Paid € 181,745 in corporate taxes since 2023.
Best year ever: 2025, with € 301,561 profit.
Management
Behind Rayos Medicinal are Jan Van der Heyden and Vanessa Schelfhout. The same people are also behind Dr. Van der Heyden Jan. Jan Van der Heyden is also behind CATHLAB.
Directors
According to the 2025 annual accounts
since 2022
since 2022
Establishments
Establishment units
Physical locations of this company
Asterstraat 17
8300 Knokke-Heist
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0792.959.360
- VAT number
- BE 0792.959.360
- Registered office
- Asterstraat 17, 8300 Knokke-Heist
- Names & denominations
- Rayos Medicinal
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 October 2022
- Peppol
- Active · Active since 20 Mar 2025